(Q37932048)

25 August 2017

1 reference

title

Specific microbicides in the prevention of HIV infection (English)

1 reference

25 August 2017

main subject

prevention of HIV/AIDS

0 references

author name string

C G Kelly

series ordinal

1

1 reference

25 August 2017

R J Shattock

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

27 October 2011

1 reference

Journal of Internal Medicine

25 August 2017

published in

1 reference

25 August 2017

volume

270

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

509-519

1 reference

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

SAVVY® (C31G) Gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Early events in sexual transmission of HIV and SIV and opportunities for interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Setting the stage: host invasion by HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Barriers to mucosal transmission of immunodeficiency viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Which topical microbicides for blocking HIV-1 transmission will work in the real world?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Large-scale manufacture of peptide therapeutics by chemical synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Targeting chemokine receptors in HIV: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Strategies in the design of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Targeting early infection to prevent HIV-1 mucosal transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Structural and molecular interactions of CCR5 inhibitors with CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Chemokine analogues show suitable stability for development as microbicides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Molecular mechanisms of HIV integration and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

The structural biology of HIV assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Microbicides and HIV prevention: lessons from the past, looking to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Advances in microbicide vaginal rings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Cell entry and export of nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Impact of drug transporters on cellular resistance towards saquinavir and darunavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

Safety and Availability of Dapivirine (TMC120) Delivered from an Intravaginal Ring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

HIV blocked by chemokine antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02454.X

10.1111/J.1365-2796.2011.02454.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference